1. Volume 18, Issue 3, Pages 347-356 (March 2017)
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial 
Dr Robert Glynne-Jones, FRCR, Prof David Sebag-Montefiore, FRCR, Helen M Meadows, MSc, Prof David Cunningham, MD, Rubina Begum, BSc, Fawzi Adab, FRCR, Kim Benstead, MD, Robert J Harte, MD, Jill Stewart, FRCR, Sandy Beare, PhD, Prof Allan Hackshaw, MSc, Latha Kadalayil, PhD 
The Lancet Oncology 
Volume 18, Issue 3, Pages (March 2017)
DOI: /S (17)
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

2. Figure 1 Treatment and assessment schedule in ACT II
*Patients referred for surgical salvage as appropriate.
The Lancet Oncology  , DOI: ( /S (17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

3. Figure 2
Overall survival according to response at assessments 1, 2, and 3 among all 940 patients in whom response data were known
cCR=complete clinical response. HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

4. Figure 3
Progression-free survival according to response at assessments 1, 2, and 3 among all 940 patients in whom response data were known
cCR=complete clinical response. HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions